
KYTX Stock Forecast & Price Target
KYTX Analyst Ratings
Bulls say
Kyverna Therapeutics Inc. is gaining substantial credibility in the biopharmaceutical sector with its innovative cell therapy products, specifically KYV-101 and KYV-201, targeting autoimmune diseases. Recent data from key opinion leaders (KOLs) has elevated the probability of approval for KYV-101 in myasthenia gravis (MG) to 35%, reflecting enhanced confidence in its performance and safety, as well as its strong clinical responses in compassionate-use scenarios. Additionally, the promising efficacy of KYV-101 compared to traditional treatments, such as rituximab, reinforces its potential as a leading therapeutic option across multiple indications within immunology and inflammatory diseases.
Bears say
Kyverna Therapeutics Inc's stock outlook is negatively impacted by several fundamental risks associated with its product candidates. The potential lack of durable responses in patients treated with KYV-101 for conditions such as lupus nephritis (LN) and myasthenia gravis (MG) raises concerns about the efficacy and long-term viability of the therapy, especially as data matures. Additionally, the company faces the risk of failing to generate positive results for KYV-101 in a third indication, systemic lupus erythematosus (SPS), alongside the looming threat of long-term dilution that may affect shareholder value.
This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KYTX Analyst Forecast & Price Prediction
Start investing in KYTX
Order type
Buy in
Order amount
Est. shares
0 shares